ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)

Clinical trials for ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) explained in plain language.

Never miss a new study

Get alerted when new ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) trials appear

Sign up with your email to follow new studies for ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New hope offered to patients with advanced ALK-Positive cancers through expanded access program

Disease control AVAILABLE

This program provides access to an investigational drug called neladalkib for patients with advanced ALK-positive cancers, including lung cancer. It is for adults who have tried other treatments without success and cannot join a formal clinical trial. The goal is to offer a poten…

Matched conditions: ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)

Sponsor: Nuvalent Inc. • Aim: Disease control

Last updated Mar 30, 2026 14:34 UTC

ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)

Get alerted when new ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) trials appear

New hope offered to patients with advanced ALK-Positive cancers through expanded access program